Bacille-Calmette-Guerin non-responders: how to manage

Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). Our goal is to describe the various disease states following induction and maintenance BCG and to describe contemporary treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: von Rundstedt, Friedrich-Carl, Lerner, Seth P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708234/
https://www.ncbi.nlm.nih.gov/pubmed/26816828
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.05.03
Descripción
Sumario:Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). Our goal is to describe the various disease states following induction and maintenance BCG and to describe contemporary treatment options and the current and projected clinical trial landscape for patients who recur following BCG therapy.

Ejemplares similares